These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24671790)

  • 1. Multicenter evaluation of the Quidel Lyra Direct C. difficile nucleic acid amplification assay.
    Beck ET; Buchan BW; Riebe KM; Alkins BR; Pancholi P; Granato PA; Ledeboer NA
    J Clin Microbiol; 2014 Jun; 52(6):1998-2002. PubMed ID: 24671790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Illumigene, Simplexa, and AmpliVue Clostridium difficile molecular assays for diagnosis of C. difficile infection.
    Deak E; Miller SA; Humphries RM
    J Clin Microbiol; 2014 Mar; 52(3):960-3. PubMed ID: 24352999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter evaluation of the Verigene Clostridium difficile nucleic acid assay.
    Carroll KC; Buchan BW; Tan S; Stamper PD; Riebe KM; Pancholi P; Kelly C; Rao A; Fader R; Cavagnolo R; Watson W; Goering RV; Trevino EA; Weissfeld AS; Ledeboer NA
    J Clin Microbiol; 2013 Dec; 51(12):4120-5. PubMed ID: 24088862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of toxigenic Clostridium difficile: comparison of the cell culture neutralization, Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays.
    Pancholi P; Kelly C; Raczkowski M; Balada-Llasat JM
    J Clin Microbiol; 2012 Apr; 50(4):1331-5. PubMed ID: 22278839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Premarket evaluations of the IMDx C. difficile for Abbott m2000 Assay and the BD Max Cdiff Assay.
    Stellrecht KA; Espino AA; Maceira VP; Nattanmai SM; Butt SA; Wroblewski D; Hannett GE; Musser KA
    J Clin Microbiol; 2014 May; 52(5):1423-8. PubMed ID: 24554744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and clinical validation of an automated cell cytotoxicity neutralization assay for detecting Clostridioides difficile toxins in clinically relevant stools samples.
    Elfassy A; Kalina WV; French R; Nguyen H; Tan C; Sebastian S; Wilcox MH; Davies K; Kutzler MA; Jansen KU; Anderson A; Pride MW
    Anaerobe; 2021 Oct; 71():102415. PubMed ID: 34298152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loop-mediated isothermal amplification compared to real-time PCR and enzyme immunoassay for toxigenic Clostridium difficile detection.
    Boyanton BL; Sural P; Loomis CR; Pesta C; Gonzalez-Krellwitz L; Robinson-Dunn B; Riska P
    J Clin Microbiol; 2012 Mar; 50(3):640-5. PubMed ID: 22189114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosing Clostridioides difficile infections with molecular diagnostics: multicenter evaluation of revogene C. difficile assay.
    Sambri V; Gateau C; Zannoli S; Dirani G; Couturier J; Op den Buijs I; Roymans R; Hallet E; Arnold M; Zumoberhaus A; Steiner S; van de Bovenkamp J; Altwegg M; Berlinger L; Barbut F;
    Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1169-1175. PubMed ID: 32062723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a loop-mediated isothermal amplification assay for diagnosis of Clostridium difficile infections.
    Lalande V; Barrault L; Wadel S; Eckert C; Petit JC; Barbut F
    J Clin Microbiol; 2011 Jul; 49(7):2714-6. PubMed ID: 21525213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular test based on isothermal helicase-dependent amplification for detection of the Clostridium difficile toxin A gene.
    Eckert C; Holscher E; Petit A; Lalande V; Barbut F
    J Clin Microbiol; 2014 Jul; 52(7):2386-9. PubMed ID: 24759714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Simplexa universal direct PCR with cytotoxicity assay for diagnosis of Clostridium difficile infection: performance, cost, and correlation with disease.
    Landry ML; Ferguson D; Topal J
    J Clin Microbiol; 2014 Jan; 52(1):275-80. PubMed ID: 24226924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the cobas Cdiff Test for Detection of Toxigenic Clostridium difficile in Stool Samples.
    Peterson LR; Young SA; Davis TE; Wang ZX; Duncan J; Noutsios C; Liesenfeld O; Osiecki JC; Lewinski MA
    J Clin Microbiol; 2017 Dec; 55(12):3426-3436. PubMed ID: 28954901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the illumigene C. difficile assay for toxigenic Clostridium difficile detection: a prospective study of 302 consecutive clinical fecal samples.
    Hong G; Park KS; Ki CS; Lee NY
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):177-80. PubMed ID: 25241189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multicenter Study of the Revogene C. difficile System for Detection of the Toxin B Gene from Unformed Stool Specimens.
    Mashock MJ; Faron ML; Carroll KC; Dang C; Lewis S; Salimnia H; Lephart P; Loo VG; Schmitt BH; Young S; Buchan BW; Ledeboer NA
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31776191
    [No Abstract]   [Full Text] [Related]  

  • 15. Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens.
    Buchan BW; Mackey TL; Daly JA; Alger G; Denys GA; Peterson LR; Kehl SC; Ledeboer NA
    J Clin Microbiol; 2012 Dec; 50(12):3932-6. PubMed ID: 23015667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a new molecular test, the BD Max Cdiff, for detection of toxigenic Clostridium difficile in fecal samples.
    Le Guern R; Herwegh S; Grandbastien B; Courcol R; Wallet F
    J Clin Microbiol; 2012 Sep; 50(9):3089-90. PubMed ID: 22760042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms.
    Novak-Weekley SM; Marlowe EM; Miller JM; Cumpio J; Nomura JH; Vance PH; Weissfeld A
    J Clin Microbiol; 2010 Mar; 48(3):889-93. PubMed ID: 20071552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity.
    Humphries RM; Uslan DZ; Rubin Z
    J Clin Microbiol; 2013 Mar; 51(3):869-73. PubMed ID: 23269736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples.
    Stamper PD; Alcabasa R; Aird D; Babiker W; Wehrlin J; Ikpeama I; Carroll KC
    J Clin Microbiol; 2009 Feb; 47(2):373-8. PubMed ID: 19073875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of loop-mediated isothermal amplification assay for detection of Clostridioides difficile infection: A prospective diagnostic performance study.
    Girão ES; Vásconez Noguera SL; Sanchez Espinoza EP; Pereira Alves Madeira Bezerra CL; Lino FM; Côrtes MF; Alves Dos Santos S; Paranhos-Baccala G; Perdigão Neto LV; Costa SF
    Anaerobe; 2021 Oct; 71():102410. PubMed ID: 34174401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.